Neonc Technologies Holdings, Inc. (NTHI)

US — Healthcare Sector
Peers:

Automate Your Wheel Strategy on NTHI

With Tiblio's Option Bot, you can configure your own wheel strategy including NTHI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol NTHI
  • Rev/Share 0.0057
  • Book/Share -0.5307
  • PB -10.9864
  • Debt/Equity 0.0
  • CurrentRatio 0.4074
  • ROIC 4.785

 

  • MktCap 110926098.0
  • FreeCF/Share -0.3766
  • PFCF -16.2396
  • PE -2.1425
  • Debt/Assets 0.0
  • DivYield 0
  • ROE 5.7409

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs
NTHI
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral

USC brain tumor authority to accelerate four clinical trials including lead asset NEO100 nearing Phase 2a completion ahead of schedule

Read More
image for news NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs

About Neonc Technologies Holdings, Inc. (NTHI)

  • IPO Date 2025-03-26
  • Website https://www.neonctech.com
  • Industry Biotechnology
  • CEO Thomas C. Chen
  • Employees 8
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.